• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Xenon Pharmaceuticals Inc. - Common Shares (NQ:XENE)

    37.75 -1.44 (-3.67%)
    Delayed Quote Updated: 3:37 PM EST, Nov 5, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Xenon Pharmaceuticals Inc. - Common Shares

    < Previous 1 2 3 4 5 Next >
    News headline image
    Xenon to Present at Upcoming Investor Conferences
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon to Report Q3 2026 Financial Results on November 9, 2026
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law
    From Schall, Brown & Schwartz LLP
    Via Business Wire
    News headline image
    Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon to Present at Wells Fargo Healthcare Conference
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon Reports Q2 2026 Financial Results and Provides Business Update
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon to Report Q2 2026 Financial Results on August 6, 2026
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon Reports Q1 2026 Financial Results and Provides Business Update
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon to Report Q1 2026 Financial Results on May 7, 2026
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon to Present at Upcoming Investor Conferences
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon Pharmaceuticals Announces Proposed Public Offering
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    News headline image
    Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.